Dynamic neuroendocrine responses to critical illness

Frontiers in Neuroendocrinology

Volumn 23, Issue 4, 2002, Pages 370-391

  Van Den Berghe, Greet ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Critical illness; Insulin resistance; Luteinizing hormone; Neuroendocrine; Pituitary hormones; Pituitary adrenal axis; Prolactin; Secretagogues; Somatotropic axis; TSH thyroid axis

Indexed keywords

GONADORELIN; GONADOTROPIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HYPOPHYSIS HORMONE; INSULIN; LIOTHYRONINE; PROTIRELIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; TESTOSTERONE; THYROTROPIN; THYROXINE;

ADENOHYPOPHYSIS; CRITICAL ILLNESS; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOPHYSIS FUNCTION; MORBIDITY; MORTALITY; NEUROENDOCRINE SYSTEM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSATILE HORMONE RELEASE; REVIEW; SURVIVAL; TREATMENT OUTCOME; WASTING SYNDROME;

EID: 0036431611     PISSN: 00913022     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3022(02)00006-7     Document Type: Article

References (93)

1. A. Aakvaag, O. Bentdal, K. Quigstad, P. Walstad, H. Ronningen, F. Fonnum, Testosterone and testosterone binding globulin in young men during prolonged stress, Int. J. Androl. 1 (1978) 22-31.
2. R. Arem, G.J. Wiener, S.G. Kaplan, H.S. Kim, S. Reichlin, M.M. Kaplan, Reduced tissue thyroid hormone levels in fatal illness, Metabolism 42 (1993) 1102-1108.
3. V. Bacci, G.C. Schussler, T.C. Kaplan, The relationship between serum triiodothyronine and thyrotropin during systemic illness, J. Clin. Endocrinol. Metab. 54 (1982) 1229-1235.
4. E. Barquist, O. Kirton, Adrenal insufficiency in the surgical intensive care unit patient, J. Trauma 42 (1997) 27-31.
5. L. Bartalena, E. Martino, L.S. Brandi, M. Falcone, A. Pacchiarotti, C. Ricci, F. Bogazzi, L. Grasso, Lack of nocturnal serum thyrotropin surge after surgery, J. Clin. Endocrinol. Metab. 70 (1990) 293-296.
6. R.C. Baxter, Circulating binding proteins for the insulin-like growth factors, Trends Endocrinol. Metab. 4 (1993) 91-96.
7. R.C. Baxter, F.H. Hawker, C. To, P.M. Stewart, S.R. Holman, Thirty-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients, Growth Horm. IGF Res. 8 (1998) 455-463.
8. R.A. Becker, G.M. Vaughan, M.G. Ziegler, L.G. Seraile, I.W. Goldfarb, E.H. Mansour, W.F. McManus, B.A. Pruitt Jr., A.D. Mason Jr., Hypermetabolic low triiodothyronine syndrome in burn injury, Crit. Care Med. 10 (1982) 870-875.
9. P.E. Belchetz, T.M. Plant, Y. Nakai, E.J. Keogh, E. Knobil, Hypophyseal responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone, Science 202 (1978) 631-633.
10. J. Bentham, Rodriguez-Arnao-J, R.J. Ross, Acquired growth hormone resistance in patients with hypercatabolism, Horm. Res. 40 (1993) 87-91.
11. E.W. Bernton, M.S. Meltzer, J.W. Holaday, Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice, Science 239 (1988) 401-404.
12. M. Bettendorf, K.G. Schmidt, J. Grulich-Henn, H.E. Ulmer, U.K. Heinrich, Tri-iodothyronine treatment in children after cardiac surgery: A double-blind, randomised, placebo-controlled study, Lancet 356 (2000) 529-534.
13. C.Y. Bowers, F.A. Momany, G.A. Reynolds, G. Hong, On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone, Endocrinology 114 (1984) 1537-1545.
14. G.A. Brent, J.M. Hershman, Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration, J. Clin. Endocrinol. Metab. 63 (1986) 1-8.
15. M. Carrier, J. Wild, C. Pelletier, J.G. Copeland, Bromocriptine as an adjuvant to cyclosporine immunosuppression after heart transplantation, Ann. Thorac. Surg. 49 (1990) 129-132.
16. P.V. Carroll, Protein metabolism and the use of growth hormone and insulin-like growth factor-I in the critically ill patient, Growth Horm. IGF Res. 9 (1999) 400-413.
17. I.J. Chopra, T.S. Huang, A. Beredo, D.H. Solomon, G.N. Chua Teco, J.F. Mead, Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,30-triiodothyronine in sera of patients with nonthyroidal illness, J. Clin. Endocrinol. Metab. 60 (1985) 666-672.
18. T.J. Cicero, R.D. Bell, W.G. Wiest, J.H. Allison, K. Polakoski, E. Robins, Function of the male sex organs in heroin and methadone users, N. Engl. J. Med. 292 (1975) 882-887.
19. P. Damas, A. Reuter, P. Gysen, J. Demonty, M. Lamy, P. Franchimont, Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans, Crit. Care Med. 17 (1989) 975-978.
20. L.J. De Groot, Dangerous dogmas in medicine: The nonthyroidal illness syndrome, J. Clin. Endocrinol. Metab. 84 (1999) 151-164.
21. P.J.D. Delhanty, R.C. Baxter, The regulation of acid-labile subunit gene expression and secretion by cyclic adenosine 3′,5′-monophosphate, Endocrinology 139 (1998) 260-265.
22. S.S. Devins, A. Miller, B.L. Herndon, L. O'Toole, G. Reisz, Effects of dopamine on T-lymphocyte proliferative responses and serum prolactin concentrations in critically ill patients, Crit. Care Med. 20 (1992) 1644-1649.
23. Q. Dong, F. Hawker, D. McWilliam, M. Bangah, H. Burger, D.J. Handelsman, Circulating immunoreactive inhibin and testosterone levels in patients with critical illness, Clin. Endocrinol. 36 (1992) 399-404.
24. G. Faglia, C. Ferrari, P. Beck-Peccoz, A. Spada, P. Travaglini, B. Ambrosi, Reduced plasma thyrotropin response to thyrotropin releasing hormone after dexamethasone administration in normal humans, Horm. Metab. Res. 5 (1973) 289-292.
25. E. Fliers, S.E. Guldenaar, W.M. Wiersinga, D.F. Swaab, Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness, J. Clin. Endocrinol. Metab. 82 (1997) 4032-4036.
26. D.F. Gardner, M.M. Kaplan, C.A. Stanley, R.D. Utiger, Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation, N. Engl. J. Med. 300 (1979) 579-584.
27. E.F. Gevers, J.M. Wit, I.C. Robinson, Growth, growth hormone (GH) binding protein, and GH receptors are differentially regulated by peak and trough components of GH secretory pattern in the rat, Endocrinology 137 (1996) 1013-1018.
28. A. Giustina, J.D. Veldhuis, Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human, Endocrinol. Rev. 19 (1998) 717-797.
29. H. Guo, J.H. Calkins, M.M. Sigel, T. Lin, Interleukin-2 is a potent inhibitor of Leydig cell steroidogenesis, Endocrinology 127 (1990) 1234-1239.
30. M.L. Hartman, J.D. Veldhuis, M.L. Johnson, M.M. Lee, K.G. Alberti, E. Samojlik, M.O. Thorner, Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men, J. Clin. Endocrinol. Metab. 74 (1992) 757-765.
31. M. Hermansson, R.B. Wickelgren, F. Hammarqvist, R. Bjarnasson, I. Wennstrom, J. Wernerman, B. Carlsson, L.M. Carlsson, Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: Demonstration of reduced expression after elective surgery, J. Clin. Endocrinol. Metab. 82 (1997) 421-428.
32. A.D. Howard, S.D. Feighner, D.F. Cully, J.P. Arena, P.A. Liberator, C.I. Rosenblum, M. Hamelin, D.L. Hreniuk, O.C. Palyha, J. Anderson, P.S. Paress, C. Diaz, M. Chou, K.K. Liu, K.K. McKee, S.S. Pong, L.Y. Chuang, A. Elbrecht, M. Dashkevicz, R. Heavens, M. Rigby, D.J. Sirinathsinghji, D.C. Dean, D.G. Melillo, L.H.T. Van der Ploeg, A receptor in pituitary and hypothalamus that functions in growth hormone release, Science 273 (1996) 974-977.
33. M. Hu, D.G. Robertson, L.J. Murphy, Growth hormone modulates insulin regulation of hepatic insulin-like growth factor binding protein-1 transcription, Endocrinology 137 (1996) 3702-3709.
34. J.D. Klemperer, I. Klein, M. Gomez, R.E. Helm, K. Ojamaa, S.J. Thomas, O.W. Isom, K. Krieger, Thyroid hormone treatment after coronary-artery bypass surgery, N. Engl. J. Med. 333 (1995) 1522-1527.
35. A. Klibanski, I.Z. Beitins, T. Badger, R. Little, J.W. McArthur, Reproductive function during fasting in man, J. Clin. Endocrinol. Metab. 53 (1981) 258-263.
36. W.A. Knaus, E.A. Draper, D.P. Wagner, J.E. Zimmerman, APACHE II: A severity of disease classification system, Crit. Care Med. 13 (1985) 818-829.
37. M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, K. Kangawa, Ghrelin is a growth-hormone-releasing acylated peptide from stomach, Nature 402 (1999) 656-660.
38. L.E. Kreuz, R.M. Rose, J.R. Jennings, Suppression of plasma testosterone levels and psychological stress. A longitudinal study of young men in Officer Candidate School, Arch. Gen. Psychiatry 26 (1972) 479-482.
39. E.D. Lephart, C.R. Baxter, C.R. Parker Jr., Effect of burn trauma on adrenal and testicular steroid hormone production, J. Clin. Endocrinol. Metab. 64 (1987) 842-848.
40. M.S. Lewitt, R.C. Baxter, Regulation of growth hormone-independent insulin-like growth factor-binding protein (BP-28) in cultured human fetal liver explants, J. Clin. Endocrinol. Metab. 69 (1989) 246-252.
41. M.S. Lewitt, R.C. Baxter, Inhibitors of glucose uptake stimulate the production of insulin-like growth factor binding protein (IGFBP-1) by human fetal liver, Endocrinology 126 (1990) 1527-1533.
42. C.F. Lim, R. Docter, T.J. Visser, E.P. Krenning, B. Bernard, H. van Toor, M. de Jong, G. Hennemann, Inhibition of thyroxine transport into cultured rat hepatocytes by serum of nonuremic critically ill patients: Effects of bilirubin and nonesterified fatty acids, J. Clin. Endocrinol. Metab. 76 (1993) 1165-1172.
43. J.L. Meakins, J.B. Pietsch, O. Bubenick, R. Kelly, H. Rode, J. Gordon, L.D. MacLean, Delayed hypersensitivity: Indicator of acquired failure of host defenses in sepsis and trauma, Ann. Surg. 188 (1977) 241-250.
44. M. Michalaki, A. Vagenakis, F. Kalfarentoz, M. Makri, V. Kyriazopoulou, Is there any role of IL-6, TNFa and cortisol in the pathogenesis of euthyroid sick syndrome?, in: Proceedings of the 81st Annual Meeting of the Endocrine Society June 12-15 1999, San Diego, CA, USA, 1999, Abstract P3-422.
45. D. Micic, V. Popovic, M. Doknic, D. Macut, C. Dieguez, F.F. Casanueva, Preserved growth hormone (GH) secretion in aged and very old subjects after testing with the combined stimulus GH-releasing hormone plus GH-releasing hexapeptide-6, J. Clin. Endocrinol. Metab. 83 (1998) 2569-2572.
46. S.L. Mullis-Jansson, M. Argenziano, S. Corwin, S. Homma, A.D. Weinberg, M. Williams, E.A. Rose, C.R. Smith, A randomized double-blind study on the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery, J. Thorac. Cardiovasc. Surg. 117 (1999) 1128-1134.
47. G.L. Noel, H.K. Suh, J.G. Stone, A.G. Frantz, Human prolactin and growth hormone release during surgery and other conditions of stress, J. Clin. Endocrinol. Metab. 35 (1972) 840-851.
48. H. Norrelund, S. Fisker, N. Vahl, J. Borglum, B. Richelsen, J.S. Christiansen, J.O. Jorgensen, Evidence supporting a direct suppressive effect of growth hormone on serum IGFBP-1 levels, experimental studies in normal, obese and GH-deficient adults, Growth Horm. IGF Res. 9 (1999) 52-60.
49. E. O'Leary, K. Hubbard, W. Tormey, A.J. Cunningham, Laparoscopic cholecystectomy: Haemodynamic and neuroendocrine responses after pneumoperitoneum and changes in position, Br. J. Anaesth. 76 (1996) 640-644.
50. H. Olivecrona, A. Hilding, C. Ekström, H. Barle, B. Nyberg, C. Moller, P.J. Delhunty, R.C. Baxter, B. Angelin, T.J. Ekström, M. Tally, Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: Serum levels and hepatic messenger ribonucleic acid responses in humans, J. Clin. Endocrinol. Metab. 84 (1999) 553-560.
51. L.N. Parker, E.R. Levin, E.T. Lifrak, Evidence for adrenocortical adaptation to severe illness, J. Clin. Endocrinol. Metab. 60 (1985) 947-952.
52. C. Rivier, W. Vale, In the rat, interleukin-1 alpha acts at the level of the brain and the gonads to interfere with gonadotropin and sex steroid secretion, Endocrinology 124 (1989) 2105-2109.
53. J. Rodriguez-Arnao, Y. Yarwood, C. Ferguson, J. Miell, C.J. Hinds, R.J. Ross, Reduction in circulating IGF-I and hepatic IGF-I mRNA levels after ceacal ligation and puncture are associated with differential regulation of hepatic IGF-binding protein-1, -2, and -3 mRNA levels, J. Endocrinol. 151 (1996) 287-292.
54. J.A. Romijn, W.M. Wiersinga, Decreased nocturnal surge of thyrotropin in nonthyroidal illness, J. Clin. Endocrinol. Metab. 70 (1990) 35-42.
55. R. Ross, J. Miell, E. Freeman, J. Jones, D. Matthews, M. Preece, C. Buchanan, Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-1, Clin. Endocrinol. (Oxf.) 35 (1991) 47-54.
56. P.M. Rothwell, P.G. Lawler, Prediction of outcome in intensive care patients using endocrine parameters, Crit. Care Med. 23 (1995) 78-83.
57. D.H. Russell, New aspects of prolactin and immunity: A lymphocyte-derived prolactin-like product and nuclear protein kinase C activation, Trends Pharmacol. Sci. 10 (1989) 40-44.
58. D.H. Russell, R. Kibler, L. Matrisian, D.F. Larson, B. Poulos, B.E. Magun, Prolactin receptors on human T and B lymphocytes: Antagonism of prolactin binding by cyclosporin, J. Immunol. 134 (1985) 3027-3031.
59. D.H. Russell, D.F. Larson, S.B. Cardon, J.G. Copeland, Cyclosporine inhibits prolactin induction of ornithine decarboxilase in rat tissues, Mol. Cell. Endocrinol. 35 (1984) 159-166.
60. N. Santoro, M. Filicori, W.F. Crowley Jr., Hypogonadotropic disorders in men and women: Diagnosis and therapy with pulsatile gonadotropin-releasing hormone, Endocrinol. Rev. 7 (1986) 11-23.
61. J.L. Schlienger, R. Sapin, T. Capgras, F. Gasser, J.P. Monassier, B. Hauer, P. Arnold, Evaluation of thyroid function after myocardial infarction, Ann. Endocrinol. (Paris) 52 (1991) 283-288.
62. D.I. Spratt, P. Cox, J. Orav, J. Moloney, T. Bigos, Reproductive axis suppression in acute illness is related to disease severity, J. Clin. Endocrinol. Metab. 76 (1993) 1548-1554.
63. S.J. Streat, A.H. Beddoe, G.L. Hill, Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients, J. Trauma 27 (1987) 262-266.
64. T. Suzuki, N. Suzuki, R.A. Daynes, E.G. Englemann, Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T-cells, Clin. Immunol. Immunopathol. 61 (1991) 202-211.
65. J. Takala, E. Ruokonen, N.R. Webster, M.S. Nielsen, D.F. Zandstra, G. Vundelinckx, C.J. Hinds, Increased mortality associated with growth hormone treatment in critically ill adults, N. Engl. J. Med. 341 (1999) 785-792.
66. M.O. Thorner, M.L. Vance, E.R. Laws, E. Horvath, K. Kovacs, The anterior pituitary, in: J.D. Wilson, D.W. Foster, H.M. Kronenberg, P.R. Larsen (Eds.), Williams Textbook of Endocrinology, Ninth Ed., WB Saunders, Philadelphia, 1998, pp. 249-340.
67. A.C. Timmins, A.M. Cotterill, S.C. Hughes, J.M. Holly, R.J. Ross, W. Blum, C.J. Hinds, Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein-3 protease, Crit. Care Med. 24 (1996) 1460-1466.
68. G. Van den Berghe, Novel insights into the neuroendocrinology of critical illness, Eur. J. Endocrinol. 143 (2000) 1-13.
69. G. Van den Berghe, R.C. Baxter, F. Weekers, P. Wouters, C.Y. Bowers, A. Iranmanesh, J.D. Veldhuis, R. Bouillon, The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects than treatment with GHRP-2 alone, Clin. Endocrinol. 56 (2002) 655-669.
70. G. Van den Berghe, R.C. Baxter, F. Weekers, P. Wouters, C.Y. Bowers, J.D. Veldhuis, A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness, J. Clin. Endocrinol. Metab. 85 (2000) 183-192.
71. G. Van den Berghe, F. de Zegher, R.C. Baxter, J.D. Veldhuis, P. Wouters, M. Schetz, C. Verwaest, E. Van der Vorst, P. Lauwers, R. Bouillon, C.Y. Bowers, Neuroendocrinology of prolonged critical illness: Effect of continuous thyrotropin-releasing hormone infusion and its combination with growth hormone secretagogues, J. Clin. Endocrinol. Metab. 83 (1998) 309-319.
72. G. Van den Berghe, F. de Zegher, R. Bouillon, Acute and prolonged critical illness as different neuroendocrine paradigms, J. Clin. Endocrinol. Metab. 83 (1998) 1827-1834.
73. G. Van den Berghe, F. de Zegher, C.Y. Bowers, P. Wouters, P. Muller, F. Soetens, D. Vlasselaers, M. Schetz, C. Verwaest, P. Lauwers, R. Bouillon, Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotropin-releasing hormone in critical illness, Clin. Endocrinol. (Oxf.) 45 (1996) 341-351.
74. G. Van den Berghe, F. de Zegher, P. Lauwers, Dopamine and the sick euthyroid syndrome in critical illness, Clin. Endocrinol. (Oxf.) 41 (1994) 731-737.
75. G. Van den Berghe, F. de Zegher, P. Lauwers, J.D. Veldhuis, Luteinizing hormone secretion and hypoandrogenemia in critically ill men: Effect of dopamine, Clin. Endocrinol. (Oxf.) 41 (1994) 563-569.
76. G. Van den Berghe, F. de Zegher, J.D. Veldhuis, P. Wouters, M. Awouters, W. Verbruggen, M. Schetz, C. Verwaest, P. Lauwers, R. Bouillon, C.Y. Bowers, The somatotropic axis in critical illness: Effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion, J. Clin. Endocrinol. Metab. 82 (1997) 590-599.
77. G. Van den Berghe, F. de Zegher, J.D. Veldhuis, P. Wouters, S. Gouwy, W. Stockman, F. Weekers, M. Schetz, P. Lauwers, R. Bouillon, C.Y. Bowers, Thyrotropin and prolactin release in prolonged critical illness: Dynamics of spontaneous secretion and effects of growth hormone-secretagogues, Clin. Endocrinol. (Oxf.) 47 (1997) 599-612.
78. G. Van den Berghe, F. de Zegher, P. Wouters, M. Schetz, C. Verwaest, P. Ferdinande, P. Lauwers, Dehydroepiandrosterone sulphate in critical illness: Effect of dopamine, Clin. Endocrinol. 43 (1995) 457-463.
79. G. Van den Berghe, F. Weekers, R.C. Baxter, P. Wouters, A. Iranmanesh, R. Bouillon, J.D. Veldhuis, Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness, J. Clin. Endocrinol. Metab. 86 (2001) 3217-3226.
80. G. Van den Berghe, P. Wouters, F. Weekers, S. Mohan, R.C. Baxter, J.D. Veldhuis, C.Y. Bowers, R. Bouillon, Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness, J. Clin. Endocrinol. Metab. 84 (1999) 1311-1323.
81. G. Van den Berghe, P. Wouters, F. Weekers, C. Verwaest, F. Bruyninckx, M. Schetz, D. Vlasselaers, P. Ferdinande, P. Lauwers, R. Bouillon, Intensive insulin therapy in critically ill patients, N. Engl. J. Med. 345 (2001) 1359-1367.
82. T. van der Poll, K.J. Van Zee, E. Endert, S.M. Coyle, D.M. Stiles, J.P. Pribble, M.A. Catalano, L.L. Moldawer, S.F. Lowry, Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentration in man, J. Clin. Endocrinol. Metab. 80 (1995) 1341-1346.
83. G.M. Vaughan, A.D. Mason Jr., W.F. McManus, B.A. Pruitt Jr., Alterations of mental status and thyroid hormones after thermal injury, J. Clin. Endocrinol. Metab. 60 (1985) 1221-1225.
84. J.D. Veldhuis, A. Iranmanesh, W.S. Evans, G. Lizarralde, M.O. Thorner, M.L. Vance, Amplitude suppression of the pulsatile mode of immunoradiometric luteinizing hormone release in fasting-induced hypoandrogenemia in normal men, J. Clin. Endocrinol. Metab. 76(1993) 587-593.
85. I. Vermes, A. Beishuizen, R.M. Hampsink, C. Haanen, Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: Possible role of endothelin and atrial natriuretic hormone, J. Clin. Endocrinol. Metab. 80 (1995) 1238-1242.
86. H.J. Voerman, R.J. Strack van Schijndel, H. de Boer, E.A. van der Veen, L.G. Thijs, Growth hormone: Secretion and administration in catabolic adult patients, with emphasis on the critically ill patient, Neth. J. Med. 41 (1992) 229-244.
87. A.V. Vogel, G.T. Peake, R.T. Rada, Pituitary-testicular axis dysfunction in burned men, J. Clin. Endocrinol. Metab. 60 (1985) 658-665.
88. C. Wang, V. Chan, T.F. Tse, R.T. Yeung, Effect of acute myocardial infarction on pituitary-testicular function, Clin. Endocrinol. (Oxf.) 9 (1978) 249-253.
89. C. Wang, V. Chan, R.T. Yeung, Effect of surgical stress on pituitary-testicular function, Clin. Endocrinol. (Oxf.) 9 (1978) 255-266.
90. F. Weekers, E. Van Herck, W. Koopmans, M. Michalaki, C.Y. Bowers, J.D. Veldhuis, G. Van den Berghe, A novel in vivo rabbit model of hypercatabolic critical illness reveals a bi-phasic neuroendocrine stress response, Endocrinology 143 (2002) 764-774.
91. P.D. Woolf, R.W. Hamill, J.V. McDonald, L.A. Lee, M. Kelly, Transient hypogonadotropic hypogonadism caused by critical illness, J. Clin. Endocrinol. Metab. 60 (1985) 444-450.
92. S.I. Yeoh, R.C. Baxter, Metabolic regulation of the growth hormone independent insulin-like growth factor binding protein in human plasma, Acta Endocrinol. (Copenh.) 119 (1988) 465-473.
93. R.D. Zipser, M.W. Davenport, K.L. Martin, M.L. Tuck, N.E. Warner, R.R. Swinney, C.L. Davis, R. Horton, Hyperreninemic hypoaldosteronism in the critically ill: A new entity, J. Clin. Endocrinol. Metab. 53 (1981) 867-873.